NetworkNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing standalone treatments, LIXTE is advancing a first-in-class approach designed to increase the effectiveness of chemotherapy and immunotherapy across multiple cancer indications,” reads a recent article. “At the center of LIXTE’s strategy is protein phosphatase 2A, or PP2A, an enzyme that plays a critical role in regulating cell growth, DNA repair, and survival signaling. In many cancers, PP2A activity enables tumor cells to recover from the damage caused by treatment,…
